Our partners at HalioDx SAS, an immuno-oncology diagnostic company headquartered in Marseille, France, recently announced that their diagnostic test Immunoscore® has been included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localised Colon Cancer.
Immunoscore® was considered for its ability to refine the prognosis for people in the early stages of colon cancer, in conjunction with the TNM scoring. As such, this combination of tests has led to the adjustment of the chemotherapy decision-making process for people with stage II and in low-risk stage III cancer of the colon.
“With increasing accuracy in patient’s risk of recurrence, precision medicine substantially improves therapeutic strategies”, said Pr. Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO) and co-author of guidelines. “Immunoscore® can be helpful to adjust the chemotherapy decision, notably when we have choices to make between quality of life and risk of relapse.“
Vincent Fert, CEO of HalioDx comments, “We are pleased that ESMO recognizes the extensive clinical validation of Immunoscore® in localised Colon cancer and consider it a significant milestone in our strategy to facilitate access to Immunoscore® testing through patient assistance programs and reimbursement initiatives.”
The ESMO Guidelines are updated with regularity to ensure the inclusion of the latest and most effective practices. In addition, these guidelines complement the W.H.O.’s International Agency for Research on Cancer introduction of the immune response as an important element of risk assessment for colorectal cancer, in addition to the traditional histologic parameters.
Read the official press release here.
For more information about HalioDx and Immunoscore, read HalioDx Immunoscore® is independently reviewed in Molecular Diagnosis and Therapy and Partner in the Spotlight: Halio Dx.